检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:邓巧荣[1]
出 处:《中外医疗》2015年第11期104-105,共2页China & Foreign Medical Treatment
摘 要:目的探讨右美托咪啶辅助在降低全麻病人麻醉后寒战发生率中的作用研究。方法该研究于2013年1月—2013年12月对在该院择期接受腹部外科手术治疗的患者按照数字表法随机分为研究组和对照组,其中研究组在麻醉诱导后给予右美托咪啶,而对照组则给予咪唑安定,比较两组患者术后寒战发生率。结果研究组和对照组患者在麻黄碱、去氧肾上腺素等辅助药物上无明显差异(t=1.02、0.10,P>0.05)。研究组患者的术后寒战发生率(16.67%)明显低于对照组(53.37%),且差异具有统计学意义(c^2=8.86,P<0.05)。研究组患者的疼痛VAS评分[(3.42±0.75)分]明显低于对照组[(4.69±0.88)分],且差异具有统计学意义(t=5.13,P<0.05)。结论右美托咪啶静脉注射,具备有效的镇静、镇痛作用,预防全麻患者术后寒战发生的效果优于咪唑安定,值得临床推广使用。Objective To explore the effects of dexmedetomidine-assisted in decreasing the incidence of shivering after patients with general anesthesia. Methods From January 2013 to December 2013, patients who electively accepted the abdominal surgical operation treatment in our hospital were divided into study group and control group according to randomly numeration table. The study group after induction of anesthesia administered dexmedetomidine, while the control group were given midazolam. Compared the incidence of shivering after anesthesia between the two groups.Results The study group and the control group had no significant difference in ephedrine, phenylephrine and other auxiliary drugs(t=1.02, 0.10,P〉0.05). Incidence of postoperative shivering in the study group (16.67%) was significantly lower than that of control group(53.37%), and the difference was statistically significant(X2=8.86,P〈0.05). Pain VAS score of the study group [(3.42 ± 0.75) points] was significantly lower than that of control group [(4.69 ± 0.88) points], and the difference was statistically significance(t=5.13,P〈0.05).Conclusion Dexmedetomidine intravenous injection, not only has a sedative and analgesic effect, but also the occurrence of shivering after general anesthesia is better than midazolam. It is worthy of clinical promotion.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249